Gliclazide Dust-Free Granules via Low-Temperature Extrusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations for oral gliclazide administration face issues such as lengthy and costly production processes, risk of active ingredient segregation and contamination, hazardous high-temperature extrusion, and pH-independent diffusive release mechanisms, which complicate production and efficacy.
Innovation Solution
Combining gliclazide with hydrophilic ingredients like hydroxypropyl methylcellulose and lipophilic ingredients with a low melting point to create dust-free granules suitable for compression, allowing for a single-step granulation-extrusion at low temperatures and subsequent tablet formation with a 24-hour release profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wet granulation with HPMC and multiple drying steps is used, then delayed-release matrix tablets are produced, but production time increases and production costs increase
Solution Approach 1:
The patent combines multiple production steps (granulation, drying, grading) into a single extrusion step that produces ready-to-compress granules directly, eliminating intermediate handling steps and reducing overall production time while maintaining the delayed-release functionality through controlled polymer composition
Solution Approach 2:
The patent modifies process parameters by conducting extrusion at lower temperatures (below 50°C) compared to traditional high-temperature processes, and adjusts polymer composition (HPMC viscosity 4000 cps, specific ratios of hydrophilic and lipophilic components) to achieve both process efficiency and desired release characteristics
2Ease of manufacture
If multiple handling steps are used in production, then granules can be processed, but risk of active ingredient segregation increases
Solution Approach 1:
The patent combines granulation and extrusion into a single integrated step that produces homogeneous granules with uniform active ingredient distribution, eliminating multiple transfer and handling operations that could cause segregation
Solution Approach 2:
The patent uses a composite formulation combining hydrophilic polymers (HPMC), hydrophilic ingredients (mannitol, dibasic sodium phosphate), and lipophilic ingredients (stearic acid, carnauba wax) in specific ratios to create granules with optimal flow and compression properties that maintain composition stability
3Ease of manufacture
If traditional granulation processes are used, then granules can be formed, but dust formation causes contamination and toxicity risks
Solution Approach 1:
The patent replaces traditional mechanical granulation processes that generate dust with an extrusion-based system that forms granules through a controlled melting and shaping process, significantly reducing dust formation and associated contamination risks
Solution Approach 2:
The extrusion process is conducted under controlled conditions with minimal exposure to air, and the closed-system nature of extrusion reduces the generation and dispersion of dust particles compared to open granulation processes
4Ease of manufacture
If high-temperature extrusion is used for granulation, then granules are formed, but active ingredient is damaged and working conditions become hazardous
Solution Approach 1:
The patent fundamentally changes the temperature parameter from traditional high-temperature extrusion (>100°C) to low-temperature extrusion (below 50°C), making the process suitable for temperature-sensitive active ingredients like gliclazide while maintaining granule formation effectiveness
Solution Approach 2:
The patent uses a composite material system where lipophilic ingredients (stearic acid, carnauba wax) with low melting points act as binders that become plasticized at low temperatures, enabling granule formation without subjecting the active ingredient to damaging high temperatures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies the production process, reduces handling risks, and achieves a controlled 24-hour release of the active ingredient, enhancing safety and efficiency while maintaining the stability of the active compound.
Implementation Method 1
lipophilic ingredients with a low melting point to obtain dust-free granules suitable, without further handling, for compression to form tablets
Implementation Method 2
The granules can be prepared in a single production step by granulation-extrusion at a temperature lower than 50°C
Implementation Method 3
A hydrophilic core tablet is thus obtained with a mechanism of release by means of gelification
Data Source
AI summary
Herein are described pharmaceutical formulations comprising gliclazide as the active ingredient, in combination with hydrophilic ingredients, a hydroxypropyl methylcellulose and lipophilic ingredients having a low melting point in the form of dust-free granules, which without further manipulation result suitable for the preparation of tablets.